Cited by 198Protein Kinase Regulation and GTPase SignalingSphingolipid Metabolism and SignalingPlant biochemistry and biosynthesis

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I

Open access

Zhang, Fang L., Kirschmeier, Paul, Carr, Donna, James, Linda, Bond, Richard W., Wang, Lynn, Patton, Robert, Windsor, William T., Syto, Rosalinda, Zhang, Rumin, Bishop, W. Robert·1997·Journal of Biological Chemistry

DOI 10.1074/jbc.272.15.10232

Open this paper in CoChat — free account

Abstract

Ras proteins are small GTP-binding proteins which are critical for cell signaling and proliferation. Four Ras isoforms exist: Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B. The carboxyl termini of all four isoforms are post-translationally modified by farnesyl protein transferase (FPT). Prenylation is required for oncogenic Ras to transform cells. Recently, it was reported that Ki-Ras4B is also an in vitro substrate for the related enzyme geranylgeranyl protein transferase-1 (GGPT-1) (James, G. L., Goldstein, J. L., and Brown, M. S. (1995) J. Biol. Chem. 270, 6221-6226). In the current studies, we compared the four isoforms of Ras as substrates for FPT and GGPT-1. The affinity of FPT for Ki-Ras4B (Km = 30 nM) is 10-20-fold higher than that for the other Ras isoforms. Consistent with this, when the different Ras isoforms are tested at equimolar concentrations, it requires 10-20-fold higher levels of CAAX-competitive compounds to inhibit Ki-Ras4B farnesylation. Additionally, we found that, as reported for Ki-Ras4B, N-Ras and Ki-Ras4A are also in vitro substrates for GGPT-1. Of the Ras isoforms, N-Ras is the highest affinity substrate for GGPT-1 and is similar in affinity to a standard GGPT-1 substrate terminating in leucine. However, the catalytic efficiencies of these geranylgeranylation reactions are between 15- and 140-fold lower than the corresponding farnesylation reactions, largely reflecting differences in affinity. Carboxyl-terminal peptides account for many of the properties of the Ras proteins. One interesting exception is that, unlike the full-length N-Ras protein, a carboxyl-terminal N-Ras peptide is not a GGPT-1 substrate, raising the possibility that upstream sequences in this protein may play a role in its recognition by GGPT-1. Studies with various carboxyl-terminal peptides from Ki-Ras4B suggest that both the carboxyl-terminal methionine and the upstream polylysine region are important determinants for geranylgeranylation. Furthermore, it was found that full-length Ki-Ras4B, but not other Ras isoforms, can be geranylgeranylated in vitro by FPT. These findings suggest that the different distribution of Ras isoforms and the ability of cells to alternatively process these proteins may explain in part the resistance of some cell lines to FPT inhibitors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1074/jbc.272.15.10232

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
ras GENES
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
PROTEIN PRENYLATION: Molecular Mechanisms and Functional Consequences
Zhang, F. L., & Casey, P. J. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.001325 · Cited by 2,018
Self-citation
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,775
FUNCTION AND REGULATION OF RAS
Lowy, D. R., & Willumsen, B. M. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.004223 · Cited by 1,164
A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane
Hancock, J. F., Paterson, H., & Marshall, C. J. (1990) · Cell · doi:10.1016/0092-8674(90)90294-o · Cited by 1,042
PROTEIN ISOPRENYLATION AND METHYLATION AT CARBOXYL-TERMINAL CYSTEINE RESIDUES
Clarke, S. G. (1992) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.61.070192.002035 · Cited by 893
p21ras is modified by a farnesyl isoprenoid.
Casey, P. J., Solski, P. A., Der, C. J., & Buss, J. E. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.21.8323 · Cited by 856
Inhibition of purified p21 farnesyl:protein transferase by Cys-AAX tetrapeptides
Reiss, Y., Goldstein, J. L., Seabra, M. C., Casey, P. J., & Brown, M. S. (1990) · Cell · doi:10.1016/0092-8674(90)90242-7 · Cited by 815
Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal Cells
James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., & Marsters, J. C. (1993) · Science · doi:10.1126/science.8316834 · Cited by 630

Show all 41 references

Research works printed but not linked: 5

Bos, 1989, Cancer Res., 49, 4682
Leon, 1987, Mol. Cell. Biol., 4, 1493
Manne, 1995, Oncogene, 10, 1763
Sepp-Lorenzino, 1995, Cancer Res., 55, 5302
Nagasu, 1995, Cancer Res., 55, 5310

Sorted by citations

Protein Lipidation: Occurrence, Mechanisms, Biological Functions, and Enabling Technologies
Jiang, H., Zhang, X., Chen, X., Aramsangtienchai, P., Tong, Z., & Lin, H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00750 · Cited by 518
Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome
Capell, B. C., Erdos, M. R., Madigan, J. P., Fiordalisi, J. J., Varga, R., Conneely, K. N., Gordon, L. B., Der, C. J., Cox, A. D., & Collins, F. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506001102 · Cited by 395
Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification
Roberts, P. J., Mitin, N., Keller, P. J., Chenette, E. J., Madigan, J. P., Currin, R. O., Cox, A. D., Wilson, O., Kirschmeier, P., & Der, C. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800882200 · Cited by 362
Self-citation
Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules
Ashar, H. R., James, L. J., Gray, K., Carr, D. M., Black, S., Armstrong, L., Bishop, W. R., & Kirschmeier, P. T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003469200 · Cited by 321
Self-citation
Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?
Reuter, C. W., Morgan, M. A., & Bergmann, L. (2000) · Blood · doi:10.1182/blood.v96.5.1655 · Cited by 300
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors
Basso, A. D., Kirschmeier, P. T., & Bishop, W. R. (2005) · Journal of Lipid Research · doi:10.1194/jlr.r500012-jlr200 · Cited by 297
Self-citation
Crystallographic Analysis of CaaX Prenyltransferases Complexed with Substrates Defines Rules of Protein Substrate Selectivity
Reid, T. S., Terry, K. L., Casey, P. J., & Beese, L. S. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.08.056 · Cited by 264
Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H., Brucker, M. J., Buser, C. A., Davide, J. P., DeSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M., et al. (2001) · PubMed · Cited by 239
Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer
Adjei, A. A., Mauer, A., Bruzek, L., Marks, R. S., Hillman, S., Geyer, S., Hanson, L. J., Wright, J. J., Erlichman, C., Kaufmann, S. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.075 · Cited by 219
Ras and Rap1: A tale of two GTPases
Shah, S. K., Brock, E. J., Ji, K., & Mattingly, R. R. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.005 · Cited by 217
Homoleptic Phosphoraneiminato Complexes of Rare Earth Elements as Initiators for Ring-Opening Polymerization of Lactones
Gröb, T., Seybert, G., Massa, W., Weller, F., Palaniswami, R., Greiner, A., & Dehnicke, K. (2000) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20001201)39:23 · Cited by 33
Statins Reduce Amyloid-β Production through Inhibition of Protein Isoprenylation
Ostrowski, S. M., Wilkinson, B. L., Golde, T. E., & Landreth, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702640200 · Cited by 180
Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors
Rusiñol, A. E., & Sinensky, M. S. (2006) · Journal of Cell Science · doi:10.1242/jcs.03156 · Cited by 173
Analysis of the genome to personalize therapy for melanoma
Davies, M. A., & Samuels, Y. (2010) · Oncogene · doi:10.1038/onc.2010.323 · Cited by 190
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Cloning and Characterization of a Mammalian Prenyl Protein-specific Protease
Otto, J. C., Kim, E. J.-H., Young, S. G., & Casey, P. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8379 · Cited by 164
The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling
Basso, A. D., Mirza, A., Liu, G., Long, B. J., Bishop, W. R., & Kirschmeier, P. T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503763200 · Cited by 162
Self-citation
Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
Brunner, T. B., Hahn, S. M., Gupta, A., Muschel, R. J., McKenna, W. G., & Bernhard, E. J. (2003) · PubMed · Cited by 147
RETRACTED: Downstream effectors of oncogenic ras in multiple myeloma cells
Hu, L., Shi, Y., Hsu, J.-H., Gera, J., Ness, B. V., & Lichtenstein, A. K. (2003) · Blood · doi:10.1182/blood-2002-08-2640 · Cited by 141
Retracted
Farnesyltransferase inhibitors: promises and realities
Cox, A. D. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00181-9 · Cited by 141
Ras Proteins: Recent Advances and New Functions
Rebollo, A., & Martínez‐A, C. (1999) · Blood · doi:10.1182/blood.v94.9.2971 · Cited by 140
Phase I Clinical and Pharmacologic Study of Chronic Oral Administration of the Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer
Crul, M., de Klerk, G. J., Swart, M., Veer, L. J. V., de Jong, D., Boerrigter, L., Palmer, P. A., Bol, C. J., Tan, H., GAST, G. C. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.116 · Cited by 131
Cerebrospinal Fluid Proteomic Analysis Reveals Dysregulation of Methionine Aminopeptidase-2 Expression in Human and Mouse Neurofibromatosis 1–Associated Glioma
Dasgupta, B., Yi, Y., Hegedűs, B., Weber, J. D., & Gutmann, D. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1842 · Cited by 128
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.
Lobell, R. B., Liu, D., Buser, C. A., Davide, J. P., DePuy, E., Hamilton, K., Koblan, K. S., Lee, Y., Mosser, S. D., Motzel, S. L., et al. (2002) · PubMed · Cited by 121
A Farnesyl-Protein Transferase Inhibitor Induces p21 Expression and G1 Block in p53 Wild Type Tumor Cells
Sepp‐Lorenzino, L., & Rosen, N. X. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20243 · Cited by 117
The basis for K-Ras4B binding specificity to protein farnesyl-transferase revealed by 2 Å resolution ternary complex structures
Long, S. B., Casey, P. J., & Beese, L. S. (2000) · Structure · doi:10.1016/s0969-2126(00)00096-4 · Cited by 114
Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects
Feldkamp, M. M., Lau, N. C., & Guha, A. (1999) · Oncogene · doi:10.1038/sj.onc.1203105 · Cited by 114
The Farnesyl Transferase Inhibitor SCH 66336 Induces a G2 → M or G1 Pause in Sensitive Human Tumor Cell Lines
Ashar, H. R., James, L. J., Gray, K., Carr, D. M., McGuirk, M., Maxwell, E., Black, S., Armstrong, L., Doll, R. J., Taveras, A. G., et al. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5076 · Cited by 109
Self-citation
Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Omer, C. A., Chen, Z., Diehl, R. E., Conner, M. W., Chen, H. Y., Trumbauer, M. E., Gopal-Truter, S., Seeburger, G., Bhimnathwala, H., Abrams, M. T., et al. (2000) · PubMed · Cited by 105
Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway
Kang, S. S., Palau, V. E., Lightner, J., Chakraborty, K., Stone, W. L., Campbell, S., Reddy, S. A. G., & Krishnan, K. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.008 · Cited by 102
Glioma Formation in Neurofibromatosis 1 Reflects Preferential Activation of K-RAS in Astrocytes
Dasgupta, B., Li, W., Perry, A., & Gutmann, D. H. (2005) · Cancer Research · doi:10.1158/0008-5472.236.65.1 · Cited by 98
Farnesyltransferase inhibitors: targeting the molecular basis of cancer
Oliff, A. I. (1999) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(99)00007-4 · Cited by 97
Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
Feldkamp, M. M., Lau, N. C., Roncari, L., & Guha, A. (2001) · PubMed · Cited by 92
Farnesyltransferase inhibitors versus Ras inhibitors
Gibbs, W. W., Graham, S. L., Hartman, G. D., Koblan, K. S., Kohl, N. E., Omer, C. A., & Oliff, A. I. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80010-5 · Cited by 91
High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors
Fiordalisi, J. J., Johnson, R. L., Weinbaum, C., Sakabe, K., Chen, Z., Casey, P. J., & Cox, A. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305733200 · Cited by 90
The Small GTP-Binding Protein Rho Potentiates AP-1 Transcription in T Cells
Chang, J., Pratt, J. C., Sawasdikosol, S., Kapeller, R., & Burakoff, S. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.4986 · Cited by 89
Ras biochemistry and farnesyl transferase inhibitors: a literature survey
Crul, M., de Klerk, G. J., Beijnen, J. H., & Schellens, J. H. M. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200103000-00001 · Cited by 87
Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects
Prendergast, G. C., & Oliff, A. I. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0335 · Cited by 82
Farnesyltransferase inhibitors: mechanism and applications
Rane, N. S., & Prendergast, G. C. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.12.2105 · Cited by 78
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
The Ras‐ERK pathway: Understanding site‐specific signaling provides hope of new anti‐tumor therapies
Calvo, F., Agudo‐Ibáñez, L., & Crespo, P. (2010) · BioEssays · doi:10.1002/bies.200900155 · Cited by 75
Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid
Elad, G., Paz, A., Haklai, R., Marciano, D., Cox, A. D., & Kloog, Y. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(99)00144-5 · Cited by 77
The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Gana‐Weisz, M., Halaschek-Wiener, J., Jansen, B., Elad, G., Haklai, R., & Kloog, Y. (2002) · PubMed · Cited by 72
Bcl-2 differentially targets K-, N-, and H-Ras to mitochondria in IL-2 supplemented or deprived cells: Implications in prevention of apoptosis
Rebollo, A., Pérez‐Sala, D., & Martínez‐A, C. (1999) · Oncogene · doi:10.1038/sj.onc.1202875 · Cited by 71
Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on Ras in human hepatic stellate cells
Carloni, V., Pinzani, M., Giusti, S., Romanelli, R. G., Parola, M., Bellomo, G., Failli, P., Hamilton, A. D., Sebti, S. M., Laffi, G., et al. (2000) · Hepatology · doi:10.1002/hep.510310121 · Cited by 66
Homoleptische Phosphaniminato‐Komplexe von Seltenerdelementen als Initiatoren für die ringöffnende Polymerisation von Lactonen
Gröb, T., Seybert, G., Massa, W., Weller, F., Palaniswami, R., Greiner, A., & Dehnicke, K. (2000) · Angewandte Chemie · doi:10.1002/1521-3757(20001201)112:23 · Cited by 12
Farnesylated proteins and cell cycle progression
Tamanoi, F., Kato‐Stankiewicz, J., Chen, J., Machado, I. M. P., & Thapar, N. (2001) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10067 · Cited by 65
K-Ras prenylation as a potential anticancer target
Baranyi, M., Buday, L., & Hegedűs, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09902-w · Cited by 62
Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK
Dai, Y., Rahmani, M., Pei, X., Khanna, P., Han, S. I., Mitchell, C., Dent, P., & Grant, S. (2004) · Blood · doi:10.1182/blood-2004-07-2767 · Cited by 61
HDJ-2 as a Target for Radiosensitization of Glioblastoma Multiforme Cells by the Farnesyltransferase Inhibitor R115777 and the Role of the p53/p21 Pathway
Wang, C., Liao, Y., Mischel, P. S., Iwamoto, K. S., Cacalano, N. A., & McBride, W. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0185 · Cited by 60
Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling
Shen, M., Pan, P., Li, Y., Li, D., Yu, H., & Hou, T. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.002 · Cited by 54
A Tagging-via-substrate Approach to Detect the Farnesylated Proteome Using Two-dimensional Electrophoresis Coupled with Western Blotting
Onono, F. O., Morgan, M. A., Spielmann, H. P., Andres, D., Subramanian, T., Ganser, A., & Reuter, C. W. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900597-mcp200 · Cited by 54
Therapeutic intervention and signaling
Heimbrook, D. C., & Oliff, A. I. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80152-x · Cited by 54
40 Years of RAS—A Historic Overview
Fernández‐Medarde, A., Rivas, J. D. L., & Santos, E. (2021) · Genes · doi:10.3390/genes12050681 · Cited by 57
Cytotoxic Effect of Zoledronic Acid-Loaded Bone Cement on Giant Cell Tumor, Multiple Myeloma, and Renal Cell Carcinoma Cell Lines
Zwolak, P., Manivel, J. C., Jasiński, P., Kirstein, M. N., Dudek, A. Z., Fisher, J. E., & Cheng, E. Y. (2010) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.h.01679 · Cited by 51
Chemical Biology of Lipidated Proteins
Triola, G., Waldmann, H., & Hedberg, C. (2011) · ACS Chemical Biology · doi:10.1021/cb200460u · Cited by 50
R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways
Beaupre, D. M., Cepero, E., Obeng, E. A., Boise, L., & Lichtenheld, M. G. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.179.3.2 · Cited by 49
Prenylation of Rab8 GTPase by type I and type II geranylgeranyl transferases
WILSON, A. L., Erdman, R., Castellano, F., & Maltese, W. A. (1998) · Biochemical Journal · doi:10.1042/bj3330497 · Cited by 49
Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
Lantry, L. E. (2000) · Carcinogenesis · doi:10.1093/carcin/21.1.113 · Cited by 47
Transformation by HrasG12V is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition
Chen, X., Makarewicz, J., Knauf, J. A., Johnson, L. K., & Fagin, J. A. (2013) · Oncogene · doi:10.1038/onc.2013.489 · Cited by 48
Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors
Tsimberidou, A. M., Rudek, M. A., Hong, D. S., Ng, C. S., Blair, J., Goldsweig, H. G., & Kurzrock, R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1027-4 · Cited by 46
Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy
Klochkov, S. G., Евгеньевна, Н. М., Yarla, N. S., Parvathaneni, M., Sharma, B., Tarasov, V. V., Barreto, G. E., Бачурин, С. О., Ashraf, G. M., & Aliev, G. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.010 · Cited by 46
RPR‐115135, a farnesyltransferase inhibitor, increases 5‐FU‐ cytotoxicity in ten human colon cancer cell lines: Role of p53
Russo, P., Malacarne, D., Falugi, C., Trombino, S., & O'Connor, P. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10461 · Cited by 43
Protein prenylation in an insect cell‐free protein synthesis system and identification of products by mass spectrometry
Suzuki, T., Ito, M., Ezure, T., Shikata, M., Ando, E., Utsumi, T., Tsunasawa, S., & Nishimura, O. (2007) · PROTEOMICS · doi:10.1002/pmic.200700237 · Cited by 44
Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited
Hill, B. T., Perrin, D., & Kruczynski, A. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00053-0 · Cited by 43
Evaluation of an Alkyne-containing Analogue of Farnesyl Diphosphate as a Dual Substrate for Protein-prenyltransferases
Hosokawa, A., Wollack, J. W., Zhang, Z., Chen, L., Bárány, G., & Distefano, M. D. (2007) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-007-9090-3 · Cited by 43
Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells
González‐Pérez, V., Reiner, D. J., Alan, J. K., Mitchell, C. E., Edwards, L. J., Khazak, V., Der, C. J., & Cox, A. D. (2010) · Journal of Molecular Signaling · doi:10.1186/1750-2187-5-2 · Cited by 45
How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Brock, E. J., Ji, K., Reiners, J. J., & Mattingly, R. R. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001154002 · Cited by 41
Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras
Novotny, C. J., Hamilton, G. L., McCormick, F. P., & Shokat, K. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00374 · Cited by 41
Murine Guanylate-binding Protein: Incomplete Geranylgeranyl Isoprenoid Modification of an Interferon-γ–inducible Guanosine Triphosphate-binding Protein
Stickney, J. T., & Buss, J. E. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.7.2191 · Cited by 41
Farnesyltransferase inhibitors: where are we now?
Tsimberidou, A. M., Chandhasin, C., & Kurzrock, R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.535516 · Cited by 39
Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors
Morgan, M. A., Wegner, J., Aydilek, E., Ganser, A., & Reuter, C. W. (2003) · Leukemia · doi:10.1038/sj.leu.2403022 · Cited by 39
Role of the Carboxyterminal Residue in Peptide Binding to Protein Farnesyltransferase and Protein Geranylgeranyltransferase
Roskoski, R. J., & Ritchie, P. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0768 · Cited by 38
J-104,871, a Novel Farnesyltransferase Inhibitor, Blocks Ras Farnesylation In Vivo in a Farnesyl Pyrophosphate-Competitive Manner
Yonemoto, M., Satoh, T., Arakawa, H., Suzuki‐Takahashi, I., Monden, Y., Kodera, T., Tanaka, K., Aoyama, T., Iwasawa, Y., Kamei, T., et al. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.1 · Cited by 37
Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
Nielsen, L. L., Shi, B., Hajian, G., Yaremko, B., Lipari, P., Ferrari, E., Gurnani, M., Malkowski, M. G., Chen, J., Bishop, W. R., et al. (1999) · PubMed · Cited by 36
Self-citation
Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth
Tang, R., Shuldiner, E. G., Kelly, M. R., Murray, C. W., Hebert, J. D., Andrejka, L., Tsai, M. K., Hughes, N. W., Parker, M. I., Cai, H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01049-w · Cited by 38
Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies
Badar, T., Cortes, J. E., Ravandi, F., O'Brien, S. M., Verstovšek, S., Garcia‐Manero, G., Kantarjian, H. M., & Borthakur, G. M. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.018 · Cited by 35
Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia
Morgan, M. A., Ganser, A., & Reuter, C. W. (2003) · Leukemia · doi:10.1038/sj.leu.2403024 · Cited by 35
Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma
Bono, J. S. D. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.010 · Cited by 35
Hematopoietic Cell Fate and the Initiation of Leukemic Properties in Primitive Primary Human Cells Are Influenced by Ras Activity and Farnesyltransferase Inhibition
Dorrell, C., Takenaka, K., Minden, M. D., Hawley, R. G., & Dick, J. E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.6993-7002.2004 · Cited by 34
Pre-clinical development of farnesyltransferase inhibitors
Lobell, R. B., & Kohl, N. E. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006018922878 · Cited by 34
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 34
The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01–Induced Apoptosis in Human Multiple Myeloma Cells
Pei, X., Dai, Y., Rahmani, M., Li, W., Dent, P., & Grant, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2346 · Cited by 33
CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents
Omer, C. A. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01129-2 · Cited by 33
Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins
Mattingly, R. R. (2013) · ISRN Oncology · doi:10.1155/2013/536529 · Cited by 33
Prenylated retinal ciliopathy protein RPGR interacts with PDE6δ and regulates ciliary localization of Joubert syndrome-associated protein INPP5E
Rao, K. N., Zhang, W., Li, L., Anand, M., & Khanna, H. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw281 · Cited by 32
Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay
Knight, L. A., Kurbacher, C. M., Glaysher, S., Fernando, A., Reichelt, R., Dexel, S., Reinhold, U., & Cree, I. A. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-38 · Cited by 30
Chemistry and Biology of Moverastins, Inhibitors of Cancer Cell Migration, Produced by Aspergillus
Takemoto, Y., Watanabe, H., Uchida, K., Matsumura, K., Nakae, K., Tashiro, E., Shindo, K., Kitahara, T., & Imoto, M. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.09.017 · Cited by 30
Inhibitors of Farnesyl Protein Transferase and MEK1,2 Induce Apoptosis in Fibroblasts Transformed with Farnesylated but Not Geranylgeranylated H-Ras
Brassard, D., English, J. M., Malkowski, M. G., Kirschmeier, P. T., Nagabhushan, T. L., & Bishop, W. R. (2002) · Experimental Cell Research · doi:10.1006/excr.2001.5440 · Cited by 30
Self-citation
High-Performance Liquid Chromatography/Mass Spectrometry Characterization of Ki4B-Ras in PSN-1 Cells Treated with the Prenyltransferase Inhibitor L-778,123
Buser, C. A., Dinsmore, C. J., Fernandes, C., Greenberg, I. B., Hamilton, K., Mosser, S. D., Walsh, E. S., Williams, T. M., & Koblan, K. S. (2001) · Analytical Biochemistry · doi:10.1006/abio.2000.4972 · Cited by 29
Biology, pathology, and therapeutic targeting of RAS
Rhett, J. M., Khan, I., & O’Bryan, J. P. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.05.002 · Cited by 29
Novel therapeutic targets in squamous cell carcinoma of the head and neck
Cohen, E. E. W. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.09.010 · Cited by 27
Proteomic Analysis of Bovine Brain G Protein γ Subunit Processing Heterogeneity
Cook, L. A., Schey, K. L., Wilcox, M. D., Dingus, J., Ettling, R., Nelson, T., Knapp, D. R., & Hildebrandt, J. D. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500223-mcp200 · Cited by 27
Evidence of a Role for Ki-RAS in the Stimulated Proliferation of Renal Fibroblasts
Sharpe, C. C., Dockrell, M. E. C., Scott, R. P., Noor, M., Cowsert, L. M., Monia, B. P., & Hendry, B. M. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1061186 · Cited by 27
Targeted Therapy for Melanoma: A Primer
Davies, M. A., & Gershenwald, J. E. (2010) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2010.09.003 · Cited by 26
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets
Goemans, B. F. (2005) · Blood · doi:10.1182/blood-2005-04-1640 · Cited by 26
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units
Petit, T., Izbicka, E., Lawrence, R. A., Bishop, W. R., Weitman, S. D., & Hoff, D. D. V. (1999) · Annals of Oncology · doi:10.1023/a:1008313232381 · Cited by 26
Self-citation
Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells
Thaler, R., Spitzer, S., Karlic, H., Berger, C., Klaushofer, K., & Varga, F. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.016 · Cited by 24
Working together: Farnesyl transferase inhibitors and statins block protein prenylation
Wojtkowiak, J. W. (2009) · Molecular and Cellular Pharmacology · doi:10.4255/mcpharmacol.09.01 · Cited by 24
Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells
Caraglia, M. (2005) · Frontiers in bioscience · doi:10.2741/1720 · Cited by 24

Authors: Zhang, F. L., Kirschmeier, P., Carr, D., James, L., Bond, R. W., Wang, L., Patton, R., Windsor, W. T., Syto, R., Zhang, R., & Bishop, W. R.
Corresponding author: Bishop, W. Robert
ORCID: Wang, Lynn
Windsor, William T.
Zhang, Rumin
Venue: Journal of Biological Chemistry
Publisher: Elsevier BV
Published: 1997-04
Volume: 272
Issue: 15
Pages: 10232-10239
ISSN: 0021-9258 (ISSN-L)
DOI: 10.1074/jbc.272.15.10232
OpenAlex: W2156654096
Cited by: 197
References: 41
Citations by year: 2025: 2 · 2024: 2 · 2023: 6 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 2 · 2013: 4 · 2012: 7
FWCI: 5.33
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by/4.0/ (vor, 8593 d)
Locations: Journal of Biological Chemistry (publishedVersion, cc-by)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Plant biochemistry and biosynthesis
Keywords: Ras isoforms, Ha-ras, NRAS, farnesyltransferase, protein prenylation, geranylgeranylation, CAAX motif, substrate affinity, carboxyl-terminal peptide, polylysine, oncogenic Ras, cell transformation
MeSH terms: Benzazepines, Binding Sites, Enzyme Inhibitors, Humans, Kinetics, Methionine, Piperidines, Polylysine, Transferases, Protein Prenylation, ras Proteins, Alkyl and Aryl Transferases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks